{"id":62629,"date":"2026-04-08T20:50:04","date_gmt":"2026-04-08T12:50:04","guid":{"rendered":"https:\/\/flcube.com\/?p=62629"},"modified":"2026-04-08T20:50:05","modified_gmt":"2026-04-08T12:50:05","slug":"simceres-cdh6-targeting-adc-sim0505-receives-fda-fast-track-designation-for-platinum-resistant-ovarian-cancer-advancing-global-development-with-nextcure","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=62629","title":{"rendered":"Simcere&#8217;s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure"},"content":{"rendered":"\n<p><strong>Simcere Pharmaceutical Group Limited (<a href=\"https:\/\/www.google.com\/finance\/quote\/2096:HKG\">HKG: 2096<\/a>)<\/strong> announced that its subsidiary <strong>Simcere Zaiming<\/strong> has received <strong>Fast Track designation<\/strong> from the <strong>U.S. Food and Drug Administration (FDA)<\/strong> for <strong>SIM0505<\/strong>, a novel antibody drug conjugate (ADC) targeting <strong>CDH6 (Cadherin-6)<\/strong>, for the treatment of <strong>platinum-resistant ovarian cancer<\/strong>. The designation accelerates development of the proprietary TOPOi-payload ADC, which is being advanced globally through Simcere&#8217;s strategic collaboration with <strong>NextCure, Inc. (NASDAQ: NXTC)<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone-amp-asset-profile\">Regulatory Milestone &amp; Asset Profile<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Simcere Pharmaceutical Group Limited (HKG: 2096)<\/td><\/tr><tr><td><strong>Subsidiary<\/strong><\/td><td>Simcere Zaiming<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SIM0505 \u2013 CDH6-targeting antibody drug conjugate (ADC)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>CDH6 (Cadherin-6) \u2013 tumor-associated antigen<\/td><\/tr><tr><td><strong>Payload<\/strong><\/td><td>Proprietary topoisomerase 1 inhibitor (TOPOi)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Platinum-resistant ovarian cancer<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>FDA Fast Track designation (April 2026)<\/td><\/tr><tr><td><strong>Development Stage<\/strong><\/td><td>Phase I clinical study for advanced solid tumors<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-partnership-framework\">Strategic Partnership Framework<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-global-rights-structure\">Global Rights Structure<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Territory<\/strong>: Retained by Simcere Zaiming<\/li>\n\n\n\n<li><strong>Global Rights (ex-China)<\/strong>: Exclusive license to NextCure, Inc. (June 2025 agreement)<\/li>\n\n\n\n<li><strong>Collaboration Model<\/strong>: Joint development across China and U.S. territories<\/li>\n\n\n\n<li><strong>Clinical Coordination<\/strong>: Integrated Phase I study design spanning both markets<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-development-timeline\">Development Timeline<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>June 2025<\/strong>: Strategic collaboration established with NextCure<\/li>\n\n\n\n<li><strong>2025-2026<\/strong>: Rapid advancement of Phase I clinical study<\/li>\n\n\n\n<li><strong>April 2026<\/strong>: FDA Fast Track designation secured<\/li>\n\n\n\n<li><strong>Ongoing<\/strong>: Enrollment in advanced solid tumor cohorts including ovarian cancer<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-rationale-amp-market-opportunity\">Clinical Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-platinum-resistant-ovarian-cancer-landscape\">Platinum-Resistant Ovarian Cancer Landscape<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need<\/strong>: Limited treatment options for platinum-resistant disease with poor prognosis<\/li>\n\n\n\n<li><strong>Patient Population<\/strong>: Represents approximately 70-80% of recurrent ovarian cancer cases<\/li>\n\n\n\n<li><strong>Current Standards<\/strong>: PARP inhibitors, anti-angiogenics, and chemotherapy with modest efficacy<\/li>\n\n\n\n<li><strong>Therapeutic Gap<\/strong>: High demand for novel mechanisms with improved safety profiles<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-cdh6-target-validation\">CDH6 Target Validation<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Tumor Specificity<\/strong>: CDH6 expression predominantly in tumor tissues with limited normal tissue expression<\/li>\n\n\n\n<li><strong>Ovarian Cancer Relevance<\/strong>: High CDH6 expression observed in multiple ovarian cancer subtypes<\/li>\n\n\n\n<li><strong>ADC Suitability<\/strong>: Ideal target characteristics for antibody-drug conjugate approach<\/li>\n\n\n\n<li><strong>Competitive Differentiation<\/strong>: Limited CDH6-targeting competitors in clinical development<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technical-innovation-amp-competitive-positioning\">Technical Innovation &amp; Competitive Positioning<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-proprietary-payload-technology\">Proprietary Payload Technology<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>TOPOi Payload<\/strong>: Next-generation topoisomerase 1 inhibitor with enhanced potency and stability<\/li>\n\n\n\n<li><strong>Linker Stability<\/strong>: Optimized linker technology designed to minimize off-target toxicity<\/li>\n\n\n\n<li><strong>Therapeutic Index<\/strong>: Engineered for improved safety profile compared to conventional ADCs<\/li>\n\n\n\n<li><strong>Manufacturing Scalability<\/strong>: Proprietary process enabling commercial-scale production<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-fast-track-advantages\">Fast Track Advantages<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Accelerated Review<\/strong>: Potential for rolling BLA submission and priority review<\/li>\n\n\n\n<li><strong>Enhanced FDA Interaction<\/strong>: More frequent meetings and guidance throughout development<\/li>\n\n\n\n<li><strong>Development Timeline<\/strong>: Could reduce time to market by 6-12 months<\/li>\n\n\n\n<li><strong>Commercial Premium<\/strong>: Fast Track designation supports premium pricing negotiations<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-global-commercial-strategy\">Global Commercial Strategy<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-dual-market-approach\">Dual-Market Approach<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Commercialization<\/strong>: Simcere leverages established oncology commercial infrastructure<\/li>\n\n\n\n<li><strong>International Markets<\/strong>: NextCure responsible for global development and commercialization<\/li>\n\n\n\n<li><strong>Revenue Sharing<\/strong>: Undisclosed terms with potential milestone payments and royalties<\/li>\n\n\n\n<li><strong>Market Access<\/strong>: Parallel regulatory strategies in U.S., EU, and key Asian markets<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-competitive-landscape-assessment\">Competitive Landscape Assessment<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>ADC Market Growth<\/strong>: Rapidly expanding ADC market with multiple recent approvals<\/li>\n\n\n\n<li><strong>Ovarian Cancer Focus<\/strong>: Several ADCs in development but limited CDH6-specific approaches<\/li>\n\n\n\n<li><strong>Chinese Innovation<\/strong>: Represents growing trend of Chinese biopharma innovation reaching global markets<\/li>\n\n\n\n<li><strong>Partnership Validation<\/strong>: NextCure&#8217;s exclusive global license validates asset quality and potential<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Chinese Biopharma Maturation<\/strong>: Demonstrates capability of Chinese companies to develop globally competitive ADC assets<\/li>\n\n\n\n<li><strong>Fast Track Achievement<\/strong>: Rare regulatory milestone for Chinese-developed oncology assets<\/li>\n\n\n\n<li><strong>Partnership Success<\/strong>: Validates Simcere&#8217;s strategy of selective global partnerships for international expansion<\/li>\n\n\n\n<li><strong>Pipeline Catalyst<\/strong>: Success could accelerate development of Simcere&#8217;s broader ADC pipeline<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory designations, clinical development, and partnership outcomes. Actual results may differ due to risks including clinical trial results, regulatory decisions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,16,1099,271,1478],"class_list":["post-62629","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-adc-xdc","tag-cancer","tag-hkg-2096","tag-simcere-pharmaceutical","tag-simcere-zaiming-pharmaceutical"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Simcere&#039;s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SIM0505, a novel antibody drug conjugate (ADC) targeting CDH6 (Cadherin-6), for the treatment of platinum-resistant ovarian cancer. The designation accelerates development of the proprietary TOPOi-payload ADC, which is being advanced globally through Simcere&#039;s strategic collaboration with NextCure, Inc. (NASDAQ: NXTC).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=62629\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Simcere&#039;s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure\" \/>\n<meta property=\"og:description\" content=\"Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SIM0505, a novel antibody drug conjugate (ADC) targeting CDH6 (Cadherin-6), for the treatment of platinum-resistant ovarian cancer. The designation accelerates development of the proprietary TOPOi-payload ADC, which is being advanced globally through Simcere&#039;s strategic collaboration with NextCure, Inc. (NASDAQ: NXTC).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=62629\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-04-08T12:50:04+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-04-08T12:50:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62629#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62629\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Simcere&#8217;s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure\",\"datePublished\":\"2026-04-08T12:50:04+00:00\",\"dateModified\":\"2026-04-08T12:50:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62629\"},\"wordCount\":582,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"HKG: 2096\",\"Simcere Pharmaceutical\",\"Simcere Zaiming Pharmaceutical\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62629#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62629\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=62629\",\"name\":\"Simcere's CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-04-08T12:50:04+00:00\",\"dateModified\":\"2026-04-08T12:50:05+00:00\",\"description\":\"Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SIM0505, a novel antibody drug conjugate (ADC) targeting CDH6 (Cadherin-6), for the treatment of platinum-resistant ovarian cancer. The designation accelerates development of the proprietary TOPOi-payload ADC, which is being advanced globally through Simcere's strategic collaboration with NextCure, Inc. (NASDAQ: NXTC).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62629#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=62629\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=62629#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Simcere&#8217;s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Simcere's CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure - Insight, China&#039;s Pharmaceutical Industry","description":"Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SIM0505, a novel antibody drug conjugate (ADC) targeting CDH6 (Cadherin-6), for the treatment of platinum-resistant ovarian cancer. The designation accelerates development of the proprietary TOPOi-payload ADC, which is being advanced globally through Simcere's strategic collaboration with NextCure, Inc. (NASDAQ: NXTC).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=62629","og_locale":"en_US","og_type":"article","og_title":"Simcere's CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure","og_description":"Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SIM0505, a novel antibody drug conjugate (ADC) targeting CDH6 (Cadherin-6), for the treatment of platinum-resistant ovarian cancer. The designation accelerates development of the proprietary TOPOi-payload ADC, which is being advanced globally through Simcere's strategic collaboration with NextCure, Inc. (NASDAQ: NXTC).","og_url":"https:\/\/flcube.com\/?p=62629","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-04-08T12:50:04+00:00","article_modified_time":"2026-04-08T12:50:05+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=62629#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=62629"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Simcere&#8217;s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure","datePublished":"2026-04-08T12:50:04+00:00","dateModified":"2026-04-08T12:50:05+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=62629"},"wordCount":582,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Cancer","HKG: 2096","Simcere Pharmaceutical","Simcere Zaiming Pharmaceutical"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=62629#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=62629","url":"https:\/\/flcube.com\/?p=62629","name":"Simcere's CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-04-08T12:50:04+00:00","dateModified":"2026-04-08T12:50:05+00:00","description":"Simcere Pharmaceutical Group Limited (HKG: 2096) announced that its subsidiary Simcere Zaiming has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for SIM0505, a novel antibody drug conjugate (ADC) targeting CDH6 (Cadherin-6), for the treatment of platinum-resistant ovarian cancer. The designation accelerates development of the proprietary TOPOi-payload ADC, which is being advanced globally through Simcere's strategic collaboration with NextCure, Inc. (NASDAQ: NXTC).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=62629#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=62629"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=62629#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Simcere&#8217;s CDH6-Targeting ADC SIM0505 Receives FDA Fast Track Designation for Platinum-Resistant Ovarian Cancer, Advancing Global Development with NextCure"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62629","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=62629"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62629\/revisions"}],"predecessor-version":[{"id":62630,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/62629\/revisions\/62630"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=62629"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=62629"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=62629"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}